Establishment of a Risk Signature Based on m6A RNA Methylation Regulators That Predicts Poor Prognosis in Renal Cell Carcinoma

Jingsun Wei,1,2,* Yucheng Qian,1,2,* Yang Tang,1,2 Xiaoxu Ge,1,2 Kai Jiang,1,2 Yimin Fang,1,2 Dongliang Fu,1,2 Xiangxing Kong,1 Qian Xiao,1 Kefeng Ding1,2 1Department of Colorectal Surgery and Oncology, Key Laboratory of Cancer Prevention and Intervention, Ministry of Education, The Second Affiliate...

Full description

Bibliographic Details
Main Authors: Wei J, Qian Y, Tang Y, Ge X, Jiang K, Fang Y, Fu D, Kong X, Xiao Q, Ding K
Format: Article
Language:English
Published: Dove Medical Press 2021-01-01
Series:OncoTargets and Therapy
Subjects:
Online Access:https://www.dovepress.com/establishment-of-a-risk-signature-based-on-m6a-rna-methylation-regulat-peer-reviewed-article-OTT
id doaj-5bef75648ec141a0ae77608801145ed0
record_format Article
spelling doaj-5bef75648ec141a0ae77608801145ed02021-01-14T20:11:09ZengDove Medical PressOncoTargets and Therapy1178-69302021-01-01Volume 1441342661215Establishment of a Risk Signature Based on m6A RNA Methylation Regulators That Predicts Poor Prognosis in Renal Cell CarcinomaWei JQian YTang YGe XJiang KFang YFu DKong XXiao QDing KJingsun Wei,1,2,* Yucheng Qian,1,2,* Yang Tang,1,2 Xiaoxu Ge,1,2 Kai Jiang,1,2 Yimin Fang,1,2 Dongliang Fu,1,2 Xiangxing Kong,1 Qian Xiao,1 Kefeng Ding1,2 1Department of Colorectal Surgery and Oncology, Key Laboratory of Cancer Prevention and Intervention, Ministry of Education, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, People’s Republic of China; 2Cancer Institute, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, People’s Republic of China*These authors contributed equally to this workCorrespondence: Kefeng DingDepartment of Colorectal Surgery and Oncology, Key Laboratory of Cancer Prevention and Intervention, Ministry of Education, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, Zhejiang, People’s Republic of ChinaTel/Fax +86-571-87784820Email dingkefeng@zju.edu.cnPurpose: N6-methyladenosine (m6A) modifications represent one of the most common methylation modifications, and they are mediated by m6A RNA methylation regulators. However, their functions in renal cell carcinoma (RCC) are not completely understood. The aim of this study was to investigate the effects of the regulators in RCC.Materials and Methods: The expression levels of the 13 main m6A RNA methylation regulators in RCC were detected and consensus clustering was performed to explore their relationships with RCC. Thereafter, a risk signature based on the regulators was established. This risk model was fully verified by conducting prognostic analyses using two datasets (The Cancer Genome Atlas [TCGA] and Gene Expression Omnibus [GEO] datasets) and a ROC curve analysis.Results: Of the 13 main m6A regulators, six were significantly upregulated and four were significantly downregulated in 893 RCC cases compared to 128 normal controls in the TCGA database. Consensus clustering based on the regulators identified two clusters of RCC cases, which were significantly associated with a pathological characteristic (T status). Thus, these results indicated that m6A RNA methylation regulators were associated with RCC. Thereafter, a risk model involving two of the regulators (METTL14 and WTAP) was established. The alterations in the mRNA and protein expression levels of these two regulators were further confirmed based on Human Protein Atlas data and real-time PCR in RCC and normal cell lines. The results indicated that the risk model may serve as an independent prognostic marker of overall survival, and it was also associated with clinicopathological characteristics (T status, M status, pathological stage, and gender) in RCC.Conclusion: Collectively, the results of this study indicated that the risk model (based on two m6A RNA methylation regulators) may serve as an independent prognostic indicator of RCC, which may aid further investigation into m6A RNA modification in RCC.Keywords: renal cell carcinoma, m6A methylation, TCGA, prognostic signaturehttps://www.dovepress.com/establishment-of-a-risk-signature-based-on-m6a-rna-methylation-regulat-peer-reviewed-article-OTTrenal cell carcinomam6a methylationtcgaprognostic signature
collection DOAJ
language English
format Article
sources DOAJ
author Wei J
Qian Y
Tang Y
Ge X
Jiang K
Fang Y
Fu D
Kong X
Xiao Q
Ding K
spellingShingle Wei J
Qian Y
Tang Y
Ge X
Jiang K
Fang Y
Fu D
Kong X
Xiao Q
Ding K
Establishment of a Risk Signature Based on m6A RNA Methylation Regulators That Predicts Poor Prognosis in Renal Cell Carcinoma
OncoTargets and Therapy
renal cell carcinoma
m6a methylation
tcga
prognostic signature
author_facet Wei J
Qian Y
Tang Y
Ge X
Jiang K
Fang Y
Fu D
Kong X
Xiao Q
Ding K
author_sort Wei J
title Establishment of a Risk Signature Based on m6A RNA Methylation Regulators That Predicts Poor Prognosis in Renal Cell Carcinoma
title_short Establishment of a Risk Signature Based on m6A RNA Methylation Regulators That Predicts Poor Prognosis in Renal Cell Carcinoma
title_full Establishment of a Risk Signature Based on m6A RNA Methylation Regulators That Predicts Poor Prognosis in Renal Cell Carcinoma
title_fullStr Establishment of a Risk Signature Based on m6A RNA Methylation Regulators That Predicts Poor Prognosis in Renal Cell Carcinoma
title_full_unstemmed Establishment of a Risk Signature Based on m6A RNA Methylation Regulators That Predicts Poor Prognosis in Renal Cell Carcinoma
title_sort establishment of a risk signature based on m6a rna methylation regulators that predicts poor prognosis in renal cell carcinoma
publisher Dove Medical Press
series OncoTargets and Therapy
issn 1178-6930
publishDate 2021-01-01
description Jingsun Wei,1,2,* Yucheng Qian,1,2,* Yang Tang,1,2 Xiaoxu Ge,1,2 Kai Jiang,1,2 Yimin Fang,1,2 Dongliang Fu,1,2 Xiangxing Kong,1 Qian Xiao,1 Kefeng Ding1,2 1Department of Colorectal Surgery and Oncology, Key Laboratory of Cancer Prevention and Intervention, Ministry of Education, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, People’s Republic of China; 2Cancer Institute, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, People’s Republic of China*These authors contributed equally to this workCorrespondence: Kefeng DingDepartment of Colorectal Surgery and Oncology, Key Laboratory of Cancer Prevention and Intervention, Ministry of Education, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, Zhejiang, People’s Republic of ChinaTel/Fax +86-571-87784820Email dingkefeng@zju.edu.cnPurpose: N6-methyladenosine (m6A) modifications represent one of the most common methylation modifications, and they are mediated by m6A RNA methylation regulators. However, their functions in renal cell carcinoma (RCC) are not completely understood. The aim of this study was to investigate the effects of the regulators in RCC.Materials and Methods: The expression levels of the 13 main m6A RNA methylation regulators in RCC were detected and consensus clustering was performed to explore their relationships with RCC. Thereafter, a risk signature based on the regulators was established. This risk model was fully verified by conducting prognostic analyses using two datasets (The Cancer Genome Atlas [TCGA] and Gene Expression Omnibus [GEO] datasets) and a ROC curve analysis.Results: Of the 13 main m6A regulators, six were significantly upregulated and four were significantly downregulated in 893 RCC cases compared to 128 normal controls in the TCGA database. Consensus clustering based on the regulators identified two clusters of RCC cases, which were significantly associated with a pathological characteristic (T status). Thus, these results indicated that m6A RNA methylation regulators were associated with RCC. Thereafter, a risk model involving two of the regulators (METTL14 and WTAP) was established. The alterations in the mRNA and protein expression levels of these two regulators were further confirmed based on Human Protein Atlas data and real-time PCR in RCC and normal cell lines. The results indicated that the risk model may serve as an independent prognostic marker of overall survival, and it was also associated with clinicopathological characteristics (T status, M status, pathological stage, and gender) in RCC.Conclusion: Collectively, the results of this study indicated that the risk model (based on two m6A RNA methylation regulators) may serve as an independent prognostic indicator of RCC, which may aid further investigation into m6A RNA modification in RCC.Keywords: renal cell carcinoma, m6A methylation, TCGA, prognostic signature
topic renal cell carcinoma
m6a methylation
tcga
prognostic signature
url https://www.dovepress.com/establishment-of-a-risk-signature-based-on-m6a-rna-methylation-regulat-peer-reviewed-article-OTT
work_keys_str_mv AT weij establishmentofarisksignaturebasedonm6arnamethylationregulatorsthatpredictspoorprognosisinrenalcellcarcinoma
AT qiany establishmentofarisksignaturebasedonm6arnamethylationregulatorsthatpredictspoorprognosisinrenalcellcarcinoma
AT tangy establishmentofarisksignaturebasedonm6arnamethylationregulatorsthatpredictspoorprognosisinrenalcellcarcinoma
AT gex establishmentofarisksignaturebasedonm6arnamethylationregulatorsthatpredictspoorprognosisinrenalcellcarcinoma
AT jiangk establishmentofarisksignaturebasedonm6arnamethylationregulatorsthatpredictspoorprognosisinrenalcellcarcinoma
AT fangy establishmentofarisksignaturebasedonm6arnamethylationregulatorsthatpredictspoorprognosisinrenalcellcarcinoma
AT fud establishmentofarisksignaturebasedonm6arnamethylationregulatorsthatpredictspoorprognosisinrenalcellcarcinoma
AT kongx establishmentofarisksignaturebasedonm6arnamethylationregulatorsthatpredictspoorprognosisinrenalcellcarcinoma
AT xiaoq establishmentofarisksignaturebasedonm6arnamethylationregulatorsthatpredictspoorprognosisinrenalcellcarcinoma
AT dingk establishmentofarisksignaturebasedonm6arnamethylationregulatorsthatpredictspoorprognosisinrenalcellcarcinoma
_version_ 1724337980637708288